HNSCCs are often treated with radiation; rates of response and cure are higher for patients with HPV+ compared to HPV-negative HNSCC; however, our data suggest that the majority of survival benefit is attributable to the subtype of HNSCC with highly active NF-κB (Fig. 4). This evidence concerns the gene NFKB1 and head and neck squamous cell carcinoma.